Overview

• Lions Rugby Company CEO Rudolf Straeuli confirmed an internal investigation into the prop’s adverse test.
• SAIDS classified the drug as a “specified” substance, so no provisional suspension was imposed.
• SARU says the medication was prescribed by a specialist for medical reasons and taken under team medical supervision, and it described the substance as non-performance enhancing.
• Ntlabakanye was omitted from the New Zealand tour to focus on his defense, a selection call SAIDS says was made by SARU.
• A hearing date is expected to be set this week, the player has not requested B-sample testing, and he bears the burden of proving unintentional use under anti-doping rules.